Approval · Notice of Compliance 37270 · 2026
KISQALI: Notice of Compliance 37270
Issued April 7, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37270
- Date
- April 7, 2026
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in the drug product manufacturing process.Change in the controls (in-process tests and acceptance criteria) applied during the manufacturing process involving addition of a test. Change in the shelf life for the drug product
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KISQALI | Not yet assigned | — |
Medicinal ingredients
- RIBOCICLIB SUCCINATE 200 MG per TAB